カテゴリー： Market Monitor Global, 世界, 医療/バイオ

臓器拒絶反応予防薬の世界市場見通し2023年-2029年

◆英語タイトル：Drug for Organ Rejection Prophylaxis Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8482 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：126 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Drug for Organ Rejection Prophylaxis Market 調査レポートは次の情報を含め、グローバルにおけるの臓器拒絶反応予防薬市場規模と予測を収録しています。・世界の臓器拒絶反応予防薬市場：売上、2018年-2023年、2024年-2029年
・世界の臓器拒絶反応予防薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の臓器拒絶反応予防薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「内服液」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

臓器拒絶反応予防薬のグローバル主要企業は、Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、臓器拒絶反応予防薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の臓器拒絶反応予防薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：タイプ別市場シェア、2022年
・内服液、注射剤、カプセル

世界の臓器拒絶反応予防薬市場：用途別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：用途別市場シェア、2022年
・病院、専門医院、その他

世界の臓器拒絶反応予防薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における臓器拒絶反応予防薬のグローバル売上、2018年-2023年
・主要企業における臓器拒絶反応予防薬のグローバル売上シェア、2022年
・主要企業における臓器拒絶反応予防薬のグローバル販売量、2018年-2023年
・主要企業における臓器拒絶反応予防薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Group

*************************************************************

・調査・分析レポートの概要
臓器拒絶反応予防薬市場の定義
市場セグメント
世界の臓器拒絶反応予防薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の臓器拒絶反応予防薬市場規模
世界の臓器拒絶反応予防薬市場規模：2022年 VS 2029年
世界の臓器拒絶反応予防薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの臓器拒絶反応予防薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の臓器拒絶反応予防薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：内服液、注射剤、カプセル
臓器拒絶反応予防薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門医院、その他
臓器拒絶反応予防薬の用途別グローバル売上・予測

・地域別市場分析
地域別臓器拒絶反応予防薬市場規模 2022年と2029年
地域別臓器拒絶反応予防薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Group
...

Organ rejection preventive drugs are used to prevent the immune system from attacking, destroying and clearing “alien ingredients” such as bacteria, viruses, foreign bodies, foreign tissues and artificial materials
This report aims to provide a comprehensive presentation of the global market for Drug for Organ Rejection Prophylaxis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug for Organ Rejection Prophylaxis. This report contains market size and forecasts of Drug for Organ Rejection Prophylaxis in global, including the following market information:
Global Drug for Organ Rejection Prophylaxis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drug for Organ Rejection Prophylaxis Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drug for Organ Rejection Prophylaxis companies in 2022 (%)
The global Drug for Organ Rejection Prophylaxis market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Oral Liquid Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drug for Organ Rejection Prophylaxis include Astellas Pharma US, Inc., Pfizer Inc., Bausch Health Companies Inc., Genentech, Inc., Veloxis Pharmaceuticals, AbbVie, Bristol Myers Squibb, Novartis Pharmaceuticals Corp and Sebela Pharmaceuticals Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drug for Organ Rejection Prophylaxis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug for Organ Rejection Prophylaxis Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, by Type, 2022 (%)
Oral Liquid
Injection
Capsule
Global Drug for Organ Rejection Prophylaxis Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialist Clinic
Other
Global Drug for Organ Rejection Prophylaxis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug for Organ Rejection Prophylaxis revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drug for Organ Rejection Prophylaxis revenues share in global market, 2022 (%)
Key companies Drug for Organ Rejection Prophylaxis sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drug for Organ Rejection Prophylaxis sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma US, Inc.
Pfizer Inc.
Bausch Health Companies Inc.
Genentech, Inc.
Veloxis Pharmaceuticals
AbbVie
Bristol Myers Squibb
Novartis Pharmaceuticals Corp
Sebela Pharmaceuticals Inc.
Janssen Biotech, Inc.
Astellas Pharma US, Inc.
Adienne Pharma & Biotech
Sanofi Genzyme Company
Heumann Pharma GmbH
Beijing Shuanglu Pharmaceutical Co., Ltd
North China Pharmaceutical Co., Ltd
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
Tianjin Central Pharmaceutical Co., Ltd
Nantong Jingjing Pharmaceutical Co., Ltd
Shanghai Pharmaceutical Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug for Organ Rejection Prophylaxis, market overview.
Chapter 2: Global Drug for Organ Rejection Prophylaxis market size in revenue and volume.
Chapter 3: Detailed analysis of Drug for Organ Rejection Prophylaxis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug for Organ Rejection Prophylaxis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drug for Organ Rejection Prophylaxis capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Drug for Organ Rejection Prophylaxis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drug for Organ Rejection Prophylaxis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drug for Organ Rejection Prophylaxis Overall Market Size
2.1 Global Drug for Organ Rejection Prophylaxis Market Size: 2022 VS 2029
2.2 Global Drug for Organ Rejection Prophylaxis Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drug for Organ Rejection Prophylaxis Sales: 2018-2029
3 Company Landscape
3.1 Top Drug for Organ Rejection Prophylaxis Players in Global Market
3.2 Top Global Drug for Organ Rejection Prophylaxis Companies Ranked by Revenue
3.3 Global Drug for Organ Rejection Prophylaxis Revenue by Companies
3.4 Global Drug for Organ Rejection Prophylaxis Sales by Companies
3.5 Global Drug for Organ Rejection Prophylaxis Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drug for Organ Rejection Prophylaxis Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drug for Organ Rejection Prophylaxis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drug for Organ Rejection Prophylaxis Players in Global Market
3.8.1 List of Global Tier 1 Drug for Organ Rejection Prophylaxis Companies
3.8.2 List of Global Tier 2 and Tier 3 Drug for Organ Rejection Prophylaxis Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Drug for Organ Rejection Prophylaxis Market Size Markets, 2022 & 2029
4.1.2 Oral Liquid
4.1.3 Injection
4.1.4 Capsule
4.2 By Type – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
4.2.1 By Type – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
4.2.2 By Type – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
4.2.3 By Type – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
4.3 By Type – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
4.3.1 By Type – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
4.3.2 By Type – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
4.3.3 By Type – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
4.4 By Type – Global Drug for Organ Rejection Prophylaxis Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drug for Organ Rejection Prophylaxis Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Other
5.2 By Application – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
5.2.1 By Application – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
5.2.2 By Application – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
5.2.3 By Application – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
5.3 By Application – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
5.3.1 By Application – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
5.3.2 By Application – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
5.3.3 By Application – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
5.4 By Application – Global Drug for Organ Rejection Prophylaxis Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Drug for Organ Rejection Prophylaxis Market Size, 2022 & 2029
6.2 By Region – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
6.2.1 By Region – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
6.2.2 By Region – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
6.2.3 By Region – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
6.3 By Region – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
6.3.1 By Region – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
6.3.2 By Region – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
6.3.3 By Region – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.4.2 By Country – North America Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.4.3 US Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.4.4 Canada Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.4.5 Mexico Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.5.2 By Country – Europe Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.5.3 Germany Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.4 France Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.5 U.K. Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.6 Italy Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.7 Russia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.8 Nordic Countries Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.9 Benelux Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.6.2 By Region – Asia Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.6.3 China Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.4 Japan Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.5 South Korea Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.6 Southeast Asia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.7 India Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.7.2 By Country – South America Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.7.3 Brazil Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.7.4 Argentina Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.8.3 Turkey Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.4 Israel Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.5 Saudi Arabia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.6 UAE Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Astellas Pharma US, Inc.
7.1.1 Astellas Pharma US, Inc. Company Summary
7.1.2 Astellas Pharma US, Inc. Business Overview
7.1.3 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.1.4 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.1.5 Astellas Pharma US, Inc. Key News & Latest Developments
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Company Summary
7.2.2 Pfizer Inc. Business Overview
7.2.3 Pfizer Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.2.4 Pfizer Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Inc. Key News & Latest Developments
7.3 Bausch Health Companies Inc.
7.3.1 Bausch Health Companies Inc. Company Summary
7.3.2 Bausch Health Companies Inc. Business Overview
7.3.3 Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.3.4 Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.3.5 Bausch Health Companies Inc. Key News & Latest Developments
7.4 Genentech, Inc.
7.4.1 Genentech, Inc. Company Summary
7.4.2 Genentech, Inc. Business Overview
7.4.3 Genentech, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.4.4 Genentech, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.4.5 Genentech, Inc. Key News & Latest Developments
7.5 Veloxis Pharmaceuticals
7.5.1 Veloxis Pharmaceuticals Company Summary
7.5.2 Veloxis Pharmaceuticals Business Overview
7.5.3 Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Major Product Offerings
7.5.4 Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.5.5 Veloxis Pharmaceuticals Key News & Latest Developments
7.6 AbbVie
7.6.1 AbbVie Company Summary
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Drug for Organ Rejection Prophylaxis Major Product Offerings
7.6.4 AbbVie Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.6.5 AbbVie Key News & Latest Developments
7.7 Bristol Myers Squibb
7.7.1 Bristol Myers Squibb Company Summary
7.7.2 Bristol Myers Squibb Business Overview
7.7.3 Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Major Product Offerings
7.7.4 Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.7.5 Bristol Myers Squibb Key News & Latest Developments
7.8 Novartis Pharmaceuticals Corp
7.8.1 Novartis Pharmaceuticals Corp Company Summary
7.8.2 Novartis Pharmaceuticals Corp Business Overview
7.8.3 Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Major Product Offerings
7.8.4 Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.8.5 Novartis Pharmaceuticals Corp Key News & Latest Developments
7.9 Sebela Pharmaceuticals Inc.
7.9.1 Sebela Pharmaceuticals Inc. Company Summary
7.9.2 Sebela Pharmaceuticals Inc. Business Overview
7.9.3 Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.9.4 Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.9.5 Sebela Pharmaceuticals Inc. Key News & Latest Developments
7.10 Janssen Biotech, Inc.
7.10.1 Janssen Biotech, Inc. Company Summary
7.10.2 Janssen Biotech, Inc. Business Overview
7.10.3 Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.10.4 Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.10.5 Janssen Biotech, Inc. Key News & Latest Developments
7.11 Astellas Pharma US, Inc.
7.11.1 Astellas Pharma US, Inc. Company Summary
7.11.2 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Business Overview
7.11.3 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.11.4 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.11.5 Astellas Pharma US, Inc. Key News & Latest Developments
7.12 Adienne Pharma & Biotech
7.12.1 Adienne Pharma & Biotech Company Summary
7.12.2 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Business Overview
7.12.3 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Major Product Offerings
7.12.4 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.12.5 Adienne Pharma & Biotech Key News & Latest Developments
7.13 Sanofi Genzyme Company
7.13.1 Sanofi Genzyme Company Company Summary
7.13.2 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Business Overview
7.13.3 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Major Product Offerings
7.13.4 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.13.5 Sanofi Genzyme Company Key News & Latest Developments
7.14 Heumann Pharma GmbH
7.14.1 Heumann Pharma GmbH Company Summary
7.14.2 Heumann Pharma GmbH Business Overview
7.14.3 Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Major Product Offerings
7.14.4 Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.14.5 Heumann Pharma GmbH Key News & Latest Developments
7.15 Beijing Shuanglu Pharmaceutical Co., Ltd
7.15.1 Beijing Shuanglu Pharmaceutical Co., Ltd Company Summary
7.15.2 Beijing Shuanglu Pharmaceutical Co., Ltd Business Overview
7.15.3 Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.15.4 Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.15.5 Beijing Shuanglu Pharmaceutical Co., Ltd Key News & Latest Developments
7.16 North China Pharmaceutical Co., Ltd
7.16.1 North China Pharmaceutical Co., Ltd Company Summary
7.16.2 North China Pharmaceutical Co., Ltd Business Overview
7.16.3 North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.16.4 North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.16.5 North China Pharmaceutical Co., Ltd Key News & Latest Developments
7.17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
7.17.1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Company Summary
7.17.2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Business Overview
7.17.3 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.17.4 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.17.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Key News & Latest Developments
7.18 Tianjin Central Pharmaceutical Co., Ltd
7.18.1 Tianjin Central Pharmaceutical Co., Ltd Company Summary
7.18.2 Tianjin Central Pharmaceutical Co., Ltd Business Overview
7.18.3 Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.18.4 Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.18.5 Tianjin Central Pharmaceutical Co., Ltd Key News & Latest Developments
7.19 Nantong Jingjing Pharmaceutical Co., Ltd
7.19.1 Nantong Jingjing Pharmaceutical Co., Ltd Company Summary
7.19.2 Nantong Jingjing Pharmaceutical Co., Ltd Business Overview
7.19.3 Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.19.4 Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.19.5 Nantong Jingjing Pharmaceutical Co., Ltd Key News & Latest Developments
7.20 Shanghai Pharmaceutical Group
7.20.1 Shanghai Pharmaceutical Group Company Summary
7.20.2 Shanghai Pharmaceutical Group Business Overview
7.20.3 Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Major Product Offerings
7.20.4 Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.20.5 Shanghai Pharmaceutical Group Key News & Latest Developments
8 Global Drug for Organ Rejection Prophylaxis Production Capacity, Analysis
8.1 Global Drug for Organ Rejection Prophylaxis Production Capacity, 2018-2029
8.2 Drug for Organ Rejection Prophylaxis Production Capacity of Key Manufacturers in Global Market
8.3 Global Drug for Organ Rejection Prophylaxis Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drug for Organ Rejection Prophylaxis Supply Chain Analysis
10.1 Drug for Organ Rejection Prophylaxis Industry Value Chain
10.2 Drug for Organ Rejection Prophylaxis Upstream Market
10.3 Drug for Organ Rejection Prophylaxis Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drug for Organ Rejection Prophylaxis Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Drug for Organ Rejection Prophylaxis in Global Market
Table 2. Top Drug for Organ Rejection Prophylaxis Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drug for Organ Rejection Prophylaxis Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drug for Organ Rejection Prophylaxis Revenue Share by Companies, 2018-2023
Table 5. Global Drug for Organ Rejection Prophylaxis Sales by Companies, (K Units), 2018-2023
Table 6. Global Drug for Organ Rejection Prophylaxis Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drug for Organ Rejection Prophylaxis Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Drug for Organ Rejection Prophylaxis Product Type
Table 9. List of Global Tier 1 Drug for Organ Rejection Prophylaxis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drug for Organ Rejection Prophylaxis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2018-2023
Table 15. By Type - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2024-2029
Table 16. By Application – Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2018-2023
Table 20. By Application - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2024-2029
Table 21. By Region – Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drug for Organ Rejection Prophylaxis Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2018-2023
Table 25. By Region - Global Drug for Organ Rejection Prophylaxis Sales (K Units), 2024-2029
Table 26. By Country - North America Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Drug for Organ Rejection Prophylaxis Sales, (K Units), 2018-2023
Table 29. By Country - North America Drug for Organ Rejection Prophylaxis Sales, (K Units), 2024-2029
Table 30. By Country - Europe Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Drug for Organ Rejection Prophylaxis Sales, (K Units), 2018-2023
Table 33. By Country - Europe Drug for Organ Rejection Prophylaxis Sales, (K Units), 2024-2029
Table 34. By Region - Asia Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Drug for Organ Rejection Prophylaxis Sales, (K Units), 2018-2023
Table 37. By Region - Asia Drug for Organ Rejection Prophylaxis Sales, (K Units), 2024-2029
Table 38. By Country - South America Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Drug for Organ Rejection Prophylaxis Sales, (K Units), 2018-2023
Table 41. By Country - South America Drug for Organ Rejection Prophylaxis Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Sales, (K Units), 2024-2029
Table 46. Astellas Pharma US, Inc. Company Summary
Table 47. Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 48. Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Astellas Pharma US, Inc. Key News & Latest Developments
Table 50. Pfizer Inc. Company Summary
Table 51. Pfizer Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 52. Pfizer Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Pfizer Inc. Key News & Latest Developments
Table 54. Bausch Health Companies Inc. Company Summary
Table 55. Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 56. Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Bausch Health Companies Inc. Key News & Latest Developments
Table 58. Genentech, Inc. Company Summary
Table 59. Genentech, Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 60. Genentech, Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Genentech, Inc. Key News & Latest Developments
Table 62. Veloxis Pharmaceuticals Company Summary
Table 63. Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Product Offerings
Table 64. Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Veloxis Pharmaceuticals Key News & Latest Developments
Table 66. AbbVie Company Summary
Table 67. AbbVie Drug for Organ Rejection Prophylaxis Product Offerings
Table 68. AbbVie Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. AbbVie Key News & Latest Developments
Table 70. Bristol Myers Squibb Company Summary
Table 71. Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Product Offerings
Table 72. Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Bristol Myers Squibb Key News & Latest Developments
Table 74. Novartis Pharmaceuticals Corp Company Summary
Table 75. Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Product Offerings
Table 76. Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Novartis Pharmaceuticals Corp Key News & Latest Developments
Table 78. Sebela Pharmaceuticals Inc. Company Summary
Table 79. Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 80. Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Sebela Pharmaceuticals Inc. Key News & Latest Developments
Table 82. Janssen Biotech, Inc. Company Summary
Table 83. Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 84. Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Janssen Biotech, Inc. Key News & Latest Developments
Table 86. Astellas Pharma US, Inc. Company Summary
Table 87. Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Product Offerings
Table 88. Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Astellas Pharma US, Inc. Key News & Latest Developments
Table 90. Adienne Pharma & Biotech Company Summary
Table 91. Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Product Offerings
Table 92. Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Adienne Pharma & Biotech Key News & Latest Developments
Table 94. Sanofi Genzyme Company Company Summary
Table 95. Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Product Offerings
Table 96. Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Sanofi Genzyme Company Key News & Latest Developments
Table 98. Heumann Pharma GmbH Company Summary
Table 99. Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Product Offerings
Table 100. Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Heumann Pharma GmbH Key News & Latest Developments
Table 102. Beijing Shuanglu Pharmaceutical Co., Ltd Company Summary
Table 103. Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Product Offerings
Table 104. Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Beijing Shuanglu Pharmaceutical Co., Ltd Key News & Latest Developments
Table 106. North China Pharmaceutical Co., Ltd Company Summary
Table 107. North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Product Offerings
Table 108. North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 109. North China Pharmaceutical Co., Ltd Key News & Latest Developments
Table 110. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Company Summary
Table 111. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Product Offerings
Table 112. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 113. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Key News & Latest Developments
Table 114. Tianjin Central Pharmaceutical Co., Ltd Company Summary
Table 115. Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Product Offerings
Table 116. Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 117. Tianjin Central Pharmaceutical Co., Ltd Key News & Latest Developments
Table 118. Nantong Jingjing Pharmaceutical Co., Ltd Company Summary
Table 119. Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Product Offerings
Table 120. Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 121. Nantong Jingjing Pharmaceutical Co., Ltd Key News & Latest Developments
Table 122. Shanghai Pharmaceutical Group Company Summary
Table 123. Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Product Offerings
Table 124. Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 125. Shanghai Pharmaceutical Group Key News & Latest Developments
Table 126. Drug for Organ Rejection Prophylaxis Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 127. Global Drug for Organ Rejection Prophylaxis Capacity Market Share of Key Manufacturers, 2021-2023
Table 128. Global Drug for Organ Rejection Prophylaxis Production by Region, 2018-2023 (K Units)
Table 129. Global Drug for Organ Rejection Prophylaxis Production by Region, 2024-2029 (K Units)
Table 130. Drug for Organ Rejection Prophylaxis Market Opportunities & Trends in Global Market
Table 131. Drug for Organ Rejection Prophylaxis Market Drivers in Global Market
Table 132. Drug for Organ Rejection Prophylaxis Market Restraints in Global Market
Table 133. Drug for Organ Rejection Prophylaxis Raw Materials
Table 134. Drug for Organ Rejection Prophylaxis Raw Materials Suppliers in Global Market
Table 135. Typical Drug for Organ Rejection Prophylaxis Downstream
Table 136. Drug for Organ Rejection Prophylaxis Downstream Clients in Global Market
Table 137. Drug for Organ Rejection Prophylaxis Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drug for Organ Rejection Prophylaxis Segment by Type in 2022
Figure 2. Drug for Organ Rejection Prophylaxis Segment by Application in 2022
Figure 3. Global Drug for Organ Rejection Prophylaxis Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drug for Organ Rejection Prophylaxis Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2029 (US$, Mn)
Figure 7. Drug for Organ Rejection Prophylaxis Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drug for Organ Rejection Prophylaxis Revenue in 2022
Figure 9. By Type - Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 11. By Type - Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 12. By Type - Global Drug for Organ Rejection Prophylaxis Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 15. By Application - Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 16. By Application - Global Drug for Organ Rejection Prophylaxis Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 20. By Region - Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 21. By Country - North America Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 22. By Country - North America Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 23. US Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 28. Germany Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 29. France Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 37. China Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 41. India Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 43. By Country - South America Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 44. Brazil Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
Figure 48. Turkey Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Drug for Organ Rejection Prophylaxis Revenue, (US$, Mn), 2018-2029
Figure 52. Global Drug for Organ Rejection Prophylaxis Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Drug for Organ Rejection Prophylaxis by Region, 2022 VS 2029
Figure 54. Drug for Organ Rejection Prophylaxis Industry Value Chain
Figure 55. Marketing Channels

※参考情報

臓器拒絶反応予防薬は、臓器移植を受けた患者において、移植された臓器が患者の免疫系によって拒絶されることを防ぐために用いられる医薬品です。臓器移植は、特に末期の臓器不全に対する有効な治療法ですが、受け取った臓器は患者の体にとっては外来の異物とみなされるため、免疫系がこれに対抗しようとします。このため、移植後に拒絶反応が起こる可能性があり、これを防ぐために拒絶反応予防薬が重要となります。

拒絶反応のメカニズムは複雑で、細胞性免疫と液性免疫の両方が関与します。細胞性免疫では、特定の白血球（T細胞）が移植された臓器の細胞を攻撃するのに対し、液性免疫では抗体が関与します。拒絶反応は急性拒絶反応と慢性拒絶反応の二つに分類されます。急性拒絶反応は移植後数日から数週間で発生し、迅速に治療が必要です。一方、慢性拒絶反応は日々進行し、数ヶ月から数年かけて臓器の機能が徐々に悪化します。

臓器拒絶反応予防薬にはいくつかの特徴があります。まず第一に、これらの薬剤は免疫抑制作用を持っており、特にT細胞やB細胞の活性化を抑制することで効果を発揮します。第二に、患者の感受性や背景疾患、移植された臓器の種類に応じて、適切な薬剤や薬剤の組み合わせを選択する必要があります。さらに、免疫抑制療法は感染症のリスクを高める可能性があるため、患者の全体的な健康状態を考慮することが不可欠です。

臓器拒絶反応予防薬には、主に以下のような種類があります。まず、コルチコステロイドは、免疫反応全体を抑制するために使用される最初の選択薬の一つです。これらは炎症を軽減し、急性拒絶反応を予防する効果があります。次に、カルシニューリン阻害剤は、T細胞の活性化に重要な役割を果たす酵素を阻害することで、免疫反応を抑制します。代表的な薬剤としてはシクロスポリンやタクロリムスがあります。

また、抗代謝薬も重要な役割を果たしています。これらの薬剤は、細胞の増殖に必要な成分を阻害することで、T細胞やB細胞の機能を抑制します。アザチオプリンやミコフェノール酸モフェチルなどが代表的です。さらに、抗体療法も臨床で利用されています。例えば、バシリキシマブやトシリズマブは、特定の白血球の機能を阻害することで免疫反応を抑制します。

臓器拒絶反応予防薬は、移植された臓器の種類や患者の状態によって異なる治療戦略が必要です。例えば、腎臓移植の場合、免疫抑制の選択肢が多く、患者の年齢、基礎疾患、腎機能などを考慮して最適な薬剤が選ばれます。心臓や肝臓の移植では、拒絶反応のリスクや副作用を慎重に評価した上で個別化された治療が求められます。

関連技術には、遺伝子療法や細胞療法が含まれています。これらの技術は、免疫系の反応を調整する新しいアプローチを提供する可能性があります。例えば、患者の免疫細胞を操作して、移植された臓器に対する耐性を高める方法や、自己免疫疾患を悪化させることなく免疫反応を抑制する方法が研究されています。

また、臓器拒絶反応予防薬の研究開発は、常に進化しています。新しい薬剤の発見や新規な投与方法の開発、バイオマーカーの特定などが進められており、将来的にはより効果的で副作用の少ない治療法が提供されることが期待されています。このような新たなアプローチは、より多くの患者が安全に移植を受けられる環境を作り出すでしょう。

臓器移植は、医療の進歩によって多くの患者の命を救うだけでなく、生活の質を向上させる可能性があります。一方で、拒絶反応予防薬の選択と管理は、移植後の長期的な成功において極めて重要です。患者と医療提供者が密に連携し、個々の患者の状況に応じた柔軟な対応が求められます。

最後に、臓器拒絶反応予防薬に関する教育や情報提供も重要です。患者自身が自らの治療選択に関与し、必要な知識を持つことで、治療の効果を高めることができます。臓器移植に関しての理解を深めることで、患者は自分自身の健康管理に貢献できるものと考えられます。これにより、より多くの人々が移植医療の恩恵を受け、充実した生活を送ることが可能になるでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 臓器拒絶反応予防薬の世界市場見通し2023年-2029年(Drug for Organ Rejection Prophylaxis Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

臓器拒絶反応予防薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp